Etid klinik pou Sklerodèm nan Illinois
11 etid pou Sklerodèm ap chèche patisipan nan sit nan Illinois.
Vil nan Illinois
Tèks ofisyèl etid la (Anglè)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Northwestern University, Chicago
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07497087A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
- University of Illinois Health Outpatient Care Center, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06655155A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Chicago
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05878717A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- The University of Chicago Medical Center (UCMC), Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Chicago
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Willowbrook, Willowbrook
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chicago
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07295847Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
- aTyr Investigative Site, Chicago
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2025 · NCT05892614Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.